Comparing standard and guided radiation therapy for liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of standard Stereotactic Body Radiation Therapy (SBRT) versus SBRT guided by radiobiological techniques in treating liver cancer. The aim is to determine if the guided approach can improve cancer control and reduce damage to healthy tissues compared to the standard method. Patients with primary hepatobiliary cancer or liver metastases will be enrolled, and their treatment outcomes will be monitored. The study seeks to provide insights into optimizing radiation therapy for better patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Eligible patients include patients with any of the following:

   * Primary hepatobiliary cancer confirmed pathologically or,
   * Non-lymphoma liver metastases confirmed pathologically or,
   * Radiographic liver lesions most consistent with metastases, in a patient with known pathologically proven non-lymphoma cancer and a previously negative CT or MRI of the liver or,
   * Hepatocellular carcinoma diagnosed with vascular enhancement of the lesion consistent with hepatocellular carcinoma, and with an elevated AFP, in the setting of cirrhosis or chronic hepatitis.
2. ≤ 5 liver lesions measurable on a contrast-enhanced liver CT or MRI performed within 90 days prior to study entry.
3. Primary liver lesion or liver metastases measuring ≤ 25 cm.
4. Extrahepatic cancer is permitted if liver involvement is judged to be life-limiting
5. No contraindications to radiotherapy
6. Patient must be judged medically or surgically unresectable
7. Zubrod Performance Scale = 0-3
8. Age \> 18
9. Systemic treatment including multikinase inhibitors and immunotherapy are allowed.

   Multikinase inhibitors must be held 2 weeks prior to radiation and may be restarted 1 week post radiation.
10. Previous liver resection or ablative therapy is permitted
11. Chemotherapy must be completed at least 2 weeks prior to radiation therapy and not planned to be administered for at least 1 week (for anthracyclines at least 4 weeks) after completion of treatment.
12. Life expectancy \> 6 months.
13. Women of childbearing potential and male participants must practice adequate contraception.

Exclusion Criteria:

1. Severe cirrhosis or liver failure defined as Child Pugh \>B7
2. Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
3. Severe, active co-morbidity, defined as limiting the patient's life to less than 6 months
4. Active hepatitis or clinically significant liver failure. Treated hepatitis is permitted.
5. Pregnancy, nursing women, or women of childbearing potential, and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be teratogenic.

Where it's running

• London Regional Cancer Program
  London, Ontario, Canada Recruiting

Study contacts

• Principal investigator: Michael Lock, MD — London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
• Study coordinator: Morgan Black
• Email: morgan.black@lhsc.on.ca
• Phone: 519-685-8500

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Assessing blood biomarkers and MRI for liver cancer patients undergoing radiation therapy

  This study is testing if using special MRI scans and blood tests can help doctors keep track of liver health in patients with liver cancer who are getting radiation therapy.

  Recruiting Montefiore Medical Center · The Bronx, New York · NCT06899152

• Using AI to improve treatment for liver tumors

  This study is testing whether using artificial intelligence can help doctors choose the best treatments and predict outcomes for patients with liver tumors undergoing thermal ablation.

  Recruiting Leiden University Medical Center · Leiden · NCT06179602

• Neoantigen vaccine combined with nivolumab for liver cancer treatment

  This study is testing a personalized vaccine combined with a cancer drug to see if it can help people with liver cancer stay cancer-free after surgery.

  Recruiting Phase 2 National Cancer Centre, Singapore · Singapore · NCT04912765

• InstaSure Non-Invasive Finger-Press Test for HCC

  This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.

  Recruiting Beijing Municipal Administration of Hospitals · Beijing, Beijing Municipality · NCT07848750

• BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer

  This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.

  Recruiting at 2 sites Phase 3 BeOne Medicines · South Brisbane, Queensland and 1 other locations · NCT07836530

• Zinc add-on with targeted therapy plus immunotherapy for advanced liver cancer

  This study tests whether adding daily zinc to standard targeted therapy and immunotherapy helps people with unresectable or advanced hepatocellular carcinoma.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07793695

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.